AndrewJacobBrennerMDPhD

Oncology • Austin, TX

Breast Cancer

Institute for Drug Development, Cancer Therapy and Research Center at UTHSCSA

Join to view full profile

Dr. Brenner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Brenner's full profile

Already have an account?

Office
901 W 38th St
Ste 200
Austin, TX 78705
Phone+1 512-421-4100

Fax+1 512-451-7380

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2008
Texas A&M College of Medicine-Scott and White Medical Center (Temple)Residency, Internal Medicine, 2003 - 2006
Texas Tech University Health Sciences Center School of MedicineClass of 2003
University of Texas at Austin Dell Medical SchoolPh.D., Tumore Biology, 1997
Texas A&M UniversityB.S., Biochemistry, 1993

Certifications & Licensure

TX State Medical License 2005 - 2025
American Board of Internal Medicine Medical Oncology
Neuro-OncologyUnited Council for Neurologic Subspecialties

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Investigator Award Cancer Therapy and Research Center at UTHSCSA, 2012
Carmela Gigliardi Scholarship National Italian American Foundation, 2000
HEB Foundation Predoctoral Fellowship, Research Division UT MD Anderson Cancer Center, Science Park, 1993
Nestor R. Bottino Award for Aptitude and Excellence in Research Texas A&M University, 1992
Outstanding Undergraduate Biochemist Texas A&M University, 1992
Join now to see all

Clinical Trials

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01
Active, not recruiting
Phase 3
A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer Start of enrollment: 2007 Nov 01
Unknown status
Phase 1
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2010 Dec 01
Completed
Phase 1, Phase 2
Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab Start of enrollment: 2011 Jun 01
Completed
Phase 2
Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma Start of enrollment: 2013 Jun 01
Completed
Phase 3
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Start of enrollment: 2013 Apr 01
Terminated
Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) Start of enrollment: 2015 Jun 03
Recruiting
Phase 1, Phase 2
ANG1005 in Patients With Recurrent High-Grade Glioma Start of enrollment: 2013 Oct 01
Completed
Phase 2
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases Start of enrollment: 2014 Apr 01
Completed
Phase 2
Impact of COX2 on Sera Biomarkers From Obese Subjects Start of enrollment: 2013 Oct 01
Completed
Early Phase 1
TH-302 in Combination With Bevacizumab for Glioblastoma Start of enrollment: 2015 May 01
Completed
Phase 2
A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) Start of enrollment: 2015 Aug 01
Completed
Phase 3
Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects Start of enrollment: 2016 Apr 01
Completed
Early Phase 1
Sacituzumab Govitecan in Recurrent Glioblastoma Start of enrollment: 2022 Jan 06
Recruiting
Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

9 citations
Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Salvador Alejo, Bridgitte E Palacios, Prabhakar Pitta Venkata, Yi He, Wenjing Li
Neuro-Oncology. 2023-07-06
461 citations
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.
David S. Hong, Yoon-Koo Kang, Mitesh J. Borad, Jasgit C. Sachdev, Samuel Ejadi
British Journal of Cancer. 2020-04-02
28 citations
Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study.
Andrew Brenner, Katherine B. Peters, James J. Vredenburgh, Felix Bokstein, Deborah T. Blumenthal
Neuro-Oncology. 2020-05-15

Lectures

Molecular profiling using the 92-gene assay for tumor classification of brain metastases.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Drug Shows Promise for Treating Brain Tumours Resulting from Breast CancerAugust 9th, 2024
Breast Cancer’s Spread to Brain Could Be Treated by Antibody-Drug ConjugateAugust 9th, 2024
Mays Cancer Center Conducts Only Clinical Trial in America of a Specific Drug Combination for Lethal Brain Cancer GlioblastomaMay 23rd, 2023
Join now to see all